Following an abbreviated submission
efavirenz 600mg, emtricitabine 200mg, tenofovir disoproxil 245mg as fumarate (Atripla) is accepted for use in NHS Scotland for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in this fixed dose combination prior to initiation of their first antiretroviral treatment regimen.
It may be used to simplify the regimen of patients for whom this combination is indicated (see above) and in whom all three agents are appropriate components at the doses provided by this fixed dose combination.
Download detailed advice59KB (PDF)
- Medicine name:
- efavirenz / emtricitabine / tenofovir disoproxil fumarate (Atripla)
- SMC ID:
- human immunodeficiency virus-1 (HIV-1) infection in adults
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Submission type
- Date advice published
- 07 April 2008